Search

Your search keyword '"Martinelli, Giovanni"' showing total 1,466 results

Search Constraints

Start Over You searched for: Author "Martinelli, Giovanni" Remove constraint Author: "Martinelli, Giovanni" Database Unpaywall Remove constraint Database: Unpaywall
1,466 results on '"Martinelli, Giovanni"'

Search Results

1. Exploring the role of the combination of FDG PET plus whole body MRI for staging newly diagnosed and relapsed/refractory multiple myeloma: A prospective trial.

2. 68Ga-PSMA PET/CT response and clinical outcomes in patients treated with enzalutamide as first-line therapy for metastatic castration-resistant prostate cancer (mCRPC): Results of a prospective study.

3. A phase 1b/2 study of pivekimab sunirine (PVEK, IMGN632) in combination with venetoclax/azacitidine for patients with newly diagnosed CD123-positive acute myeloid leukemia.

6. Unlocking the potential of synthetic patients for accelerating clinical trials: Results of the first GIMEMA experience on acute myeloid leukemia patients

7. Management of ALL in Adults: 2023 ELN Recommendations from a European Expert Panel

8. Diagnosis, Prognostic Factors and Assessment of ALL in Adults: 2023 ELN Recommendations from a European Expert Panel

10. Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial

11. ETV6::ABL1-Positive Myeloid Neoplasm: A Case of a Durable Response to Imatinib Mesylate without Additional or Previous Treatment

13. Geochemical characteristics of natural springs within the Lenglongling fault zone related to the Menyuan Ms 6.9 earthquake on January 8, 2022, NW China

14. Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study

15. Corrigendum: Evaluation of the Stellae-123 prognostic gene expression signature in acute myeloid leukemia

17. Personalizing precision medicine: Patients with AML perceptions about treatment decisions

19. P-057 Role of the combination of FDG-PET plus whole body MRI for staging newly diagnosed and relapsed/refractory multiple myeloma: a prospective trial

21. Dynamic Monitoring of Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer

23. POSTER: MM-602 Role of the Combination of FDG-PET Plus Whole Body MRI for Staging Patients With High-Risk Smoldering Myeloma: A Prospective Trial

24. P-206 3D in vitro modelling of relapsed/refractory multiple myeloma to unveil mechanisms of acquired resistance to therapy

25. Uncovering the expression of circPVT1 in the extracellular vesicles of acute myeloid leukemia patients

27. MM-602 Role of the Combination of FDG-PET Plus Whole Body MRI for Staging Patients With High-Risk Smoldering Myeloma: A Prospective Trial

30. Immuno markers in newly diagnosed glioblastoma patients underwent Stupp protocol after neurosurgery: a retrospective series

31. PB1888: TRIAL IN PROGRESS: PHASE 1B/2 STUDY OF PIVEKIMAB SUNIRINE (PVEK, IMGN632) IN COMBINATION WITH VENETOCLAX/AZACITIDINE OR MAGROLIMAB FOR PATIENTS WITH CD123-POSITIVE ACUTE MYELOID LEUKEMIA (AML)

32. P495: UNLOCKING THE POTENTIAL OF SYNTHETIC PATIENTS FOR ACCELERATING CLINICAL TRIALS: RESULTS OF THE FIRST GIMEMA EXPERIENCE

33. P523: THE COMPARISON OF VFLAI, FLAI AND 3 + 7 REGIMENS BY MULTILEVEL PROPENSITY SCORE WEIGHTING HIGHLIGHTS THE BENEFIT OF THE ADDITION OF VENETOCLAX IN NO LOW-RISK AML TREATED IN GIMEMA TRIALS AND REAL WORLD

34. S139: INTERIM ANALYSIS OF A REGISTRATION ENABLING STUDY OF PIVEKIMAB SUNIRINE (PVEK, IMGN632) A CD123-TARGETING ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN)

35. P553: PRELIMINARY RESULTS OF MRD ANALYSIS OF AML1718, A PHASE 2 OPEN-LABEL STUDY OF VENETOCLAX, FLUDARABINE, IDARUBICIN AND CYTARABINE (V-FLAI) IN THE INDUCTION THERAPY OF NON LOW-RISK AML

36. P953: ROLE OF THE COMBINATION OF FDG PET PLUS WHOLE BODY MRI FOR STAGING NEWLY DIAGNOSED AND RELAPSED/REFRACTORY MULTIPLE MYELOMA: A PROSPECTIVE TRIAL

37. P918: ROLE OF THE COMBINATION OF FDG PET PLUS WHOLE BODY MRI FOR STAGING PATIENTS IN HIGH RISK SMOLDERING MYELOMA: A PROSPECTIVE TRIAL

38. P537: SAFETY AND TOLERABILITY OF AZD0466 AS MONOTHERAPY FOR PATIENTS WITH ADVANCED HEMATOLOGICAL MALIGNANCIES - PRELIMINARY RESULTS FROM AN ONGOING PHASE I/II TRIAL

39. P547: UPFRONT INTENSIVE TREATMENT ANALYSIS OF THE ITALIAN COHORT STUDY ON FLT3-MUTATED AML PATIENTS (FLAM): THE IMPACT OF A FLT3 INHIBITOR ADDITION TO STANDARD CHEMOTHERAPY IN THE REAL-LIFE SETTING

41. P451: GENE FUSIONS AND OTHER GENOMIC EVENTS UNDERLIE VENETOCLAX AND HYPOMETHYLATING AGENT RESISTANCE AND PROVIDE NEW TARGETS IN ACUTE MYELOID LEUKEMIA.

43. MEK1/2 regulate normal BCR and ABL1 tumor-suppressor functions to dictate ATO response in TKI-resistant Ph+ leukemia

45. Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial

46. The power of telemedicine to improve CAR-T cell therapy programs: lessons learned from COVID-19 pandemic

47. Venetoclax durable response in adult relapsed/refractory Philadelphia-negative acute lymphoblastic leukemia with JAK/STAT pathway alterations

48. Digital Guardian Angel Supported by an Artificial Intelligence System to Improve Quality of Life, Well-being, and Health Outcomes of Patients With Cancer (ONCORELIEF): Protocol for a Single Arm Prospective Multicenter Pilot Study

50. Abstract 3076: Autologous ECM-composed scaffolds and zebrafish PDXs for individualized theranostics in rare neuroendocrine neoplasms

Catalog

Books, media, physical & digital resources